考虑群体免疫和性行为的瑞典性别中立HPV疫苗接种的成本效益
该研究旨在评估瑞典将HPV疫苗接种计划扩展至青春期前男孩(性别中立接种)相较于仅接种女孩的成本效益。采用动态房室模型模拟HPV16/18相关疾病负担,考虑群体免疫和性行为,时间跨度100年,成本和效果均按每年3%贴现。结果显示性别中立接种可减少HPV相关癌症和CIN,每获得一个QALY的成本为40,000欧元;按2017年采购价,性别中立接种占优。结论认为在瑞典引入性别中立HPV疫苗接种计划具有良好成本效益,其成本效益高度依赖疫苗价格。
要点
- 性别中立接种可减少HPV相关癌症和CIN,稳态下每年男女各减少约60例癌症。
- 每获得一个QALY的成本估计为40,000欧元;按2017年采购价,性别中立接种占优。
- 成本效益高度依赖疫苗价格,价格越低越有利于也接种男孩。
核心结论
- 在瑞典引入性别中立HPV疫苗接种计划具有良好成本效益,且其成本效益高度依赖疫苗价格,价格越低越有利于也接种男孩。
研究设计与样本
- 采用动态房室模型模拟瑞典HPV16/18相关疾病负担,考虑群体免疫和性行为(如年龄偏好和男男性行为者),时间跨度100年,效果和成本均按每年3%贴现。
主要发现
- 性别中立接种计划通过直接效应和群体免疫减少HPV相关癌症和CIN,稳态下每年男女各减少约60例HPV相关癌症。
- 每获得一个QALY的成本估计为40,000欧元;按2017年采购价,性别中立接种占优。
关键数值与推荐
- 主要结局为HPV相关癌症(宫颈癌、生殖器癌、肛门癌和口咽癌)和宫颈上皮内瘤变(CIN)的人数。
- 成本包括治疗HPV相关癌症和CIN的费用、病假期间的生产损失以及疫苗采购和接种费用。
- 健康效果以质量调整生命年(QALY)衡量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The aim was to assess cost-effectiveness of expanding the Swedish HPV-vaccination program to include preadolescent boys, by comparing health-effects and costs of HPV-related disease, with a sex-neutral vaccination program versus only vaccinating girls. METHODS: We used a dynamic compartmental model to simulate the burden of HPV16/18-related disease in Sweden, accounting for indirect effects of vaccination through herd-immunity. The model accounted for sexual behaviour, such as age preferences and men who have sex with men. The main outcome was number of individuals with HPV-related cancers (cervical, genital, anal and oropharyngeal cancer) and cervical intraepithelial neoplasia (CIN). Costs included in the analysis were those incurred when treating HPV-related cancer and CIN, production losses during sick-leave, and acquisition and administration of vaccine. Health effects were measured as quality-adjusted life years (QALY). The time horizon was set to 100 years, and both effects and costs were discounted by 3% annually. Health effects and costs were accumulated over the time horizon and used to create an incremental cost-effectiveness ratio. RESULTS: A sex-neutral vaccination program would reduce HPV-related cancer and CIN, both due to direct effects among vaccinated as well as through herd-immunity, further decreasing HPV-related cancer burden annually by around 60 cases among men and women respectively in steady-state. The cost per gained QALY was estimated to 40,000 euro. Applying the procurement price of 2017, sex-neutral vaccination was dominant. CONCLUSION: Introducing a sex-neutral HPV-vaccination program would be good value for money also in Sweden where there this 80% coverage in the current HPV-vaccination program for preadolescent girls. The cost-effectiveness of a sex-neutral program is highly dependent on the price of the vaccine, the lower the price the more favourable it is to also vaccinate boys.
引用
- Wolff E, Elfström KM, Haugen Cange H, et al. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. Vaccine. 2018. PMID: 30017146. doi:10.1016/j.vaccine.2018.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。